Q1 2025 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2025-05-15 · accession 0000950123-25-005509
$169.5M
Reported value
13
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G52441105 | KMTS | Kestra Med Technologies Ltd. | $44.8M | 26.4% | 1,795,893 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc. | $28.7M | 17.0% | 2,204,650 | Common | SOLE |
| 08659B102 | BBNX | Beta Bionics Inc. | $24.3M | 14.4% | 1,988,287 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio | $23.0M | 13.6% | 13,072,340 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $19.3M | 11.4% | 1,975,203 | Common | SOLE |
| 91678A107 | UPB | Upstream Bio Inc. | $12.5M | 7.35% | 2,036,293 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics | $4.1M | 2.43% | 1,184,636 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $4.0M | 2.37% | 653,223 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $2.9M | 1.70% | 2,249,123 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $2.4M | 1.39% | 526,357 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc. | $1.9M | 1.15% | 1,788,160 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $1.4M | 0.84% | 843,750 | Common | SOLE |
| 29286M113 | — | enGene Holdings Inc. | $192,901 | 0.11% | 321,502 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.